Study on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor: Eli Lilly and Company
ClinicalTrials ID:NCT07218341
This clinical trial is examining the long-term safety of the drug pirtobrutinib in patients who have already been treated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants who were part of a previous study can continue receiving the treatment or attend follow-up visits every 4 weeks for up to 5 years.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to monitor the long-term safety of pirtobrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received treatment. The study is open to those who completed a previous related study and wish to continue receiving the treatment or participate in follow-up visits. The treatment will be administered every 4 weeks, and the study is expected to last about 5 years.
Eligibility Criteria
Inclusion Criteria
- Must be currently participating in the related study J2N-MC-JZNN/LOXO-BTK-20020.
Exclusion Criteria
- This is not applicable to this study
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.